

ASX ANNOUNCEMENT

30 October 2020

Respiri Provides wheezo™ Launch Update

Respiri Limited (ASX: RSH) (“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health management, is very pleased with the response to the launch wheezo™ from pharmacists and partner Cipla.

wheezo™ is a new and innovative eHealth platform (device and app) designed to assist patients living with asthma by extending care beyond the clinic. Respiri is partnering with Cipla to support the availability of wheezo™ in selected pharmacies. wheezo™ is also available to purchase from the <https://wheezo.com/>. Currently, healthcare professionals and asthma patients have very little support at hand once a patient leaves the clinic and certainly, limited interactive tools. The wheezo™ eHealth platform aims to fill that void by providing an interactive and engaging platform to better manage the plans healthcare professionals outline for their patients.

CEO and Managing Director of Respiri, Mr Marjan Mikel commented. “The Respiri team is excited to bring to market a new and innovative product to assist with asthma management. The launch of wheezo™ marks our commitment to assist asthma patients, caregivers and health professionals to provide a solution to extended care beyond the clinic and support improved asthma care, management and understanding”. The wheezo™ launch strategy has been informed by targeted market research and insightful feedback from the wheezo™ Patient Experiential Program (PEP) and appears to be very well received”.

Managing Director of Cipla Australia, Mr Azhar Ibrahim commented that initial interest and feedback has exceeded expectations with several key banner groups coming onboard to sell wheezo™ and partnering with Cipla and Respiri to develop in-pharmacy programs to help patients with asthma better manage their condition. “It is terrific to see a product like wheezo™ now available. Our sales representatives have already received some very enthusiastic and encouraging feedback from pharmacists, with them very eager to have wheezo™ on their shelves and more importantly in the hands of patients that need it.”

To support the pharmacists, Respiri has partnered with The Pharmacy Guild of Australia, to deliver a 60-minute CPD education online course and participation in the program has been very strong with participation being more than twice the average participation rates for other Guild educational programs. The course has been developed for pharmacists to recognise the prevalence and burden of asthma in Australia, to identify the role that digital technology in assisting asthma management and positioning digital solutions for those patients who need them the most - Pharmacy.

“The entire Respiri team would like to thank all shareholders for their continued support throughout the wheezo™ journey. Respiri is extremely proud with progress to date and excited for further development and growth in the months and years to come” said Mr Mikel.

wheezo™ is available now from <https://wheezo.com> and from selected pharmacies.

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel

CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley

Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

This ASX announcement dated 30 October 2020 has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respiri's mission is to improve asthma management by extending care beyond the clinic. Respiri Limited's operations are based in Melbourne, Australia.

For additional information about Respiri and its products, please visit www.respiri.co

About wheezo

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo device records wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

™ wheezo is a trademark of Respiri Limited

About Cipla Limited and Cipla

Australia Established in 1935, Cipla Limited is a global pharmaceutical company focused on responsible and sustainable growth through deep and wide portfolio and strong patient relationships across our home markets of India, South Africa, US, Australia and other key regulated and emerging markets. Cipla Limited has the one of the world's largest range of inhaled medication and devices for respiratory disease and manufactures more than 100 million inhalers annually. Cipla's respiratory products are exported to more than 100 countries – every minute someone somewhere is using a form of Cipla medication or a delivery system. Cipla Australia, based in Melbourne, has grown to become a leading integrated generics and ethical pharmaceuticals supplier, marketer and distributor in Australia. Cipla Australia has more than 200 products listed with the TGA.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology

and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respiri only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.